Practical considerations in screening for genetic alterations in cholangiocarcinoma

Area of Science:

• Oncology
• Genomics
• Molecular Diagnostics

Background:

• Cholangiocarcinoma (CCA) is an aggressive cancer with poor outcomes, often diagnosed late.
• Limited efficacy of standard chemotherapy for advanced CCA necessitates novel therapeutic strategies.
• Comprehensive molecular profiling has identified diverse genomic alterations driving CCA development.

Purpose of the Study:

• To highlight the importance of comprehensive genomic profiling in cholangiocarcinoma (CCA).
• To discuss the utility of next-generation sequencing (NGS) for identifying actionable targets in CCA.
• To emphasize the potential for personalized targeted therapies based on molecular diagnosis.

Main Methods:

• Analysis of genomic alterations in CCA through comprehensive molecular profiling.
• Utilizing next-generation sequencing (NGS) assays for large gene panel analysis.
• Review of available and emerging targeted therapies based on identified genetic alterations.

Main Results:

• TP53 mutations, CDKN2A/B loss, and KRAS mutations are common CCA alterations.
• Intrahepatic CCA (iCCA) shows distinct actionable alterations like IDH1 mutations and FGFR2 rearrangements, unlike extrahepatic CCA (eCCA).
• FGFR2 rearrangements and IDH1 mutations represent key targets for approved or emerging therapies.

Conclusions:

• NGS-based genomic profiling provides precise molecular diagnosis for CCA.
• Identification of specific genetic alterations enables tailored targeted treatment strategies.
• Personalized medicine approaches hold promise for improving outcomes in cholangiocarcinoma.